“…Indeed, constitutively active mutants of Rab7b (Rab7bQ67L) and Rab9 (Rab9Q66L) not only localize to different target compartments (Golgi and late endosomes, respectively), but also induce opposite effects on carrier formation from the TGN with Rab9Q66L increasing and Rab7bQ67L decreasing the number of TGN-derived vesicles (Kucera et al, 2016;Progida et al, 2010Progida et al, , 2012. However, Rab7b has been much less characterized compared to Rab9, and only a few effectors have been identified, including sortilin and myosin II (Borg et al, 2014; Progida et al, 2012).…”